Drug Approval | January 14, 2022
WHO recommends two new drugs for COVID-19
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
This test analyses samples in VTM directly without the need for RNA extraction step
The stability is led by healthy demand in the domestic and emerging markets
This surpasses the number of approvals supported in 2020
Ind-Ra expects revenue growth of over 12% in 2022.
The study will be published on the pre-print server, medRXiv, shortly
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel
Subscribe To Our Newsletter & Stay Updated
